<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00522808</url>
  </required_header>
  <id_info>
    <org_study_id>CP104</org_study_id>
    <nct_id>NCT00522808</nct_id>
  </id_info>
  <brief_title>A Study of the PK, Safety and Antiviral Activity of A-831 in HCV Carriers</brief_title>
  <acronym>CP104</acronym>
  <official_title>A Clinical Pharmacology Study to Determine the Pharmacokinetic , Safety and Tolerability Profile and Antiviral Activity of Multiple Oral Doses of A-831 in Otherwise Healthy Male Hepatitis C Carriers With Compensated Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Arrow Therapeutics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>DDS, Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>David Mutimer, Birmingham</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ed Gane, ACS New Zealand</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Arrow Therapeutics</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are:

        -  to determine the safety and tolerability of multiple doses of A-831 at various doses

        -  to determine how multiple doses of A-831 are distributed through the bloodstream

        -  to determine if A-831 reduces the amount of Hepatitis C virus in the blood
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Need for re-formulation
  </why_stopped>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>PK</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Antiviral activity</measure>
  </primary_outcome>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Chronic Hepatitis C</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-831</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Volunteers will be males of any race aged 18-60 years with a BMI between 18 and 32
             kg/m2 at the time of the screening medical

          -  Volunteers who have given their written informed consent to participate in the study

          -  Volunteers who are willing and able to comply with the protocol and study procedures

          -  Volunteers who have a diagnosis of chronic hepatitis C infection and are in good
             health (other than history of Hepatitis C infection)

        Exclusion Criteria:

          -  Voulnteers with concurrent medical conditions or taking concurrent medications
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Brian Sanderson</last_name>
    <role>Principal Investigator</role>
    <affiliation>DDS</affiliation>
  </overall_official>
  <overall_official>
    <last_name>David Mutimer</last_name>
    <role>Principal Investigator</role>
    <affiliation>WTCRF Birmingham</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Edward Gane</last_name>
    <role>Principal Investigator</role>
    <affiliation>ACS New Zealand</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ACS</name>
      <address>
        <city>Auckland</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Birmingham WTCRF</name>
      <address>
        <city>Birmingham</city>
        <zip>B15 2TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DDS</name>
      <address>
        <city>Dundee</city>
        <zip>DD1 9SY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>New Zealand</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 29, 2007</study_first_submitted>
  <study_first_submitted_qc>August 29, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 30, 2007</study_first_posted>
  <last_update_submitted>September 26, 2008</last_update_submitted>
  <last_update_submitted_qc>September 26, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 29, 2008</last_update_posted>
  <responsible_party>
    <name_title>Julie Dent</name_title>
    <organization>Arrow Therapeutics</organization>
  </responsible_party>
  <keyword>HCV</keyword>
  <keyword>antiviral</keyword>
  <keyword>PK</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis, Chronic</mesh_term>
    <mesh_term>Hepatitis C, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

